Johnson & Johnson, which was a part of the wave of the primary cell therapies, is now getting a next-generation contender by paying $785 million to start out a partnership on a Sail Biomedicines cell remedy in improvement for autoimmune issues.
Along with having access to Sail’s lead program and the platform expertise that created it, J&J secured an unique possibility to accumulate the startup. The deal introduced after Wednesday’s market shut places J&J squarely within the combine of huge pharmaceutical corporations working to develop the attain of cell remedy to immunology with therapies that obtain immune system reset: depleting pathogenic cells to allow the immune system to repopulate with cells that don’t assault wholesome tissue.
The science of Cambridge, Massachusetts-based Sail comes from Flagship Pioneering, an funding agency that creates startups round platform applied sciences. In 2023, Flagship shaped Sail by merging two of its portfolio corporations, Laronde and Senda Biosciences.
Essentially the most superior program listed on Sail’s pipeline is SAIL-0839, an in vivo cell remedy designed to focus on T cells which can be constructive for CD4 and CD8. This remedy delivers RNA that reprograms these cells to precise a chimeric antigen receptor (CAR) for CD19, a protein expressed on the floor of B cells. Sail describes this RNA as “countless,” providing a long-lasting impact. The primary technology of cell therapies, together with J&J’s a number of myeloma CAR T remedy Carvykti, go after cancerous B cells, however these therapies are made in a prolonged and costly multi-step ex vivo manufacturing course of that additionally requires the affected person bear an intensive preconditioning drug routine.
In vivo cell therapies might deliver sufferers an off-the-shelf different that doesn’t require preconditioning. Biopharmaceutical corporations have been creating such therapies for autoimmune ailments. Sail has not disclosed illness targets for its applications, however B cell exercise drives many immunological issues. J&J’s announcement mentioned the Sail settlement strengthens the pharma firm’s “alternatives to advance future applications throughout a variety of complicated ailments.”
“Sail’s revolutionary platform represents an thrilling new method that seeks to harness the ability of CAR-T remedy in an easier, extra scalable manner,” John Reed, govt vp, revolutionary drugs analysis & improvement, Johnson & Johnson, mentioned in ready assertion. “By working along with Sail, we purpose to speed up the event of revolutionary therapies which have the potential to basically remodel how immune-mediated ailments are handled.”
[Paragraph updated with comment from Flagship.] Sail began constructing the case for its expertise with information introduced on the American Society of Gene & Cell Remedy annual assembly in Could. Preclinical outcomes for a CAR T-therapy named SAIL-0804 confirmed environment friendly in vivo reprogramming of T cells that was sturdy. These cells additionally led to depletion of B cells. On the time, Sail mentioned it could advance SAIL-0804 to the clinic. SAIL-0804 is not listed within the pipeline, which at present reveals the CD4- and CD8-targeting SAIL-0839 because the lead program. In an electronic mail, Flagship spokesperson Lindy Devereux confirmed that SAIL-0839 is Sail’s lead program. Whereas SAIL-0804 was the startup’s first improvement candidate, she mentioned SAIL-0839 builds on it with an optimized product profile.
J&J’s settlement with Sail continues a flurry of dealmaking for in vivo cell therapies. Final yr, AstraZeneca, AbbVie, Bristol Myers Squibb, and Gilead Sciences every acquired biotech corporations for his or her in vivo cell remedy applied sciences and applications with potential functions in immunology. Eli Lilly joined on this yr by means of the acquisition of Orna Therapeutics. The cohort of corporations pursuing immune reset through T cell engagers consists of UCB and Gilead, each of which added their contenders by means of offers this yr.
Immunology is considered one of six key therapeutics areas for J&J, and it’s the second-largest in income behind solely oncology. However the firm’s prime immunology product, Stelara, has already misplaced patent safety. The Sail deal helps construct the pharma firm’s pipeline. Below the Sail settlement, $465 million of the $785 million fee is an fairness funding within the startup. Milestone funds might add one other $140 million to the payout.
The deal additionally grants J&J an unique possibility to purchase the biotech for a further $2.58 billion. The set off for exercising that possibility was not disclosed, nevertheless it might come quickly. In a analysis be aware, Leerink Companions analyst David Risinger identified that J&J’s announcement states how a lot an acquisition would dilute earnings per share. Whereas it’s common for an buying firm to state that, the announcement consists of figures for each 2026 and 2027. Total, Risinger views the Sail settlement as “an vital step for JNJ’s immunology R&D efforts.”
J&J Closes Billion-Greenback Deal That Builds Its Most cancers Drug Pipeline
Separate from the Sail announcement, J&J mentioned it has accomplished the $1 billion acquisition of Firefly Bio, a startup creating a brand new kind of focused most cancers remedy. The pharma firm initially introduced this deal in June.
Firefly was a part of a bunch of biotech corporations creating medication in a brand new class of medicines referred to as degrader antibody drug conjugates (DACs). Constructing on antibody drug conjugates (ADCs) for most cancers, DACs make use of a drug payload that degrades a disease-driving protein. Firefly launched in 2024, backed by $94 million in Sequence A financing. J&J mentioned Firefly brings capabilities to handle tumors which have been difficult to drug, together with cancers pushed by elusive KRAS mutations.
Photograph: Mario Tama, Getty Photos
